AskBio's Ametefgene Parvec Enters Phase II Trial for Parkinson's Disease Gene Therapy

Key Takeaways

• AskBio’s Ametefgene parvec (AB-1005) advances to Phase II clinical trials for Parkinson’s disease treatment
• Viralgen facility will supply commercial-scale drug product using next-generation manufacturing process for higher purity
• The REGENERATE-PD trial represents a significant milestone in gene therapy development for neurodegenerative diseases

---

AskBio Inc., a Bayer AG subsidiary, announced April 20, 2026, that its Viralgen manufacturing facility will supply commercial-scale Ametefgene parvec (AB-1005) for the Phase II REGENERATE-PD trial targeting Parkinson’s disease.

The gene therapy company has implemented its proprietary manufacturing process at the Viralgen commercial facility, utilizing next-generation technology designed to deliver high-purity product with enhanced efficiency. This advancement marks a critical step in bringing potential gene therapy treatment to Parkinson’s patients.

Manufacturing Innovation Drives Progress

The commercial-scale production capability represents a significant leap from traditional research-grade manufacturing. AskBio’s next-generation process focuses on producing Ametefgene parvec with improved purity standards, which could translate to better safety and efficacy profiles in clinical trials.

Viralgen’s facility integration demonstrates AskBio’s commitment to scaling gene therapy manufacturing for potential commercial distribution. The company’s investment in advanced manufacturing infrastructure positions it competitively in the growing gene therapy market.

Parkinson’s Disease Treatment Landscape

Parkinson’s disease affects over 10 million people worldwide, with current treatments primarily managing symptoms rather than addressing underlying disease mechanisms. Gene therapy approaches like Ametefgene parvec aim to modify disease progression at the cellular level, potentially offering more durable therapeutic benefits.

The REGENERATE-PD Phase II trial will evaluate the investigational gene therapy’s safety and efficacy in a larger patient population, building on earlier clinical data. Success in this trial phase could accelerate the pathway toward regulatory approval and patient access.

Market Implications

AskBio’s manufacturing milestone occurs amid growing investor interest in neurodegenerative disease treatments. The gene therapy market for neurological conditions is projected to reach significant valuations as companies advance promising candidates through clinical development.

Bayer’s backing provides AskBio with substantial resources for continued development and potential commercialization. The pharmaceutical giant’s support underscores confidence in gene therapy’s potential to address unmet medical needs in Parkinson’s disease treatment.

---

Frequently Asked Questions

What does this mean for Parkinson’s patients?

The Phase II trial brings Ametefgene parvec closer to potential approval, offering hope for a treatment that could modify disease progression rather than just manage symptoms.

When will Ametefgene parvec be available to patients?

The drug is currently in Phase II trials. If successful, it would need Phase III trials and regulatory approval, typically taking several years before commercial availability.

How does gene therapy compare to current Parkinson’s treatments?

Unlike current medications that manage symptoms, gene therapy aims to address underlying disease mechanisms, potentially providing longer-lasting benefits with fewer side effects.